UK Markets close in 46 mins
  • FTSE 100

    7,463.58
    -121.43 (-1.60%)
     
  • FTSE 250

    22,171.24
    -543.74 (-2.39%)
     
  • AIM

    1,129.63
    -26.82 (-2.32%)
     
  • GBP/EUR

    1.1949
    -0.0070 (-0.58%)
     
  • GBP/USD

    1.3548
    -0.0053 (-0.3861%)
     
  • BTC-GBP

    28,585.51
    -3,448.54 (-10.77%)
     
  • CMC Crypto 200

    912.51
    +669.83 (+276.01%)
     
  • S&P 500

    4,458.62
    -24.11 (-0.54%)
     
  • DOW

    34,677.06
    -38.33 (-0.11%)
     
  • CRUDE OIL

    84.67
    -0.88 (-1.03%)
     
  • GOLD FUTURES

    1,835.80
    -6.80 (-0.37%)
     
  • NIKKEI 225

    27,522.26
    -250.64 (-0.90%)
     
  • HANG SENG

    24,965.55
    +13.20 (+0.05%)
     
  • DAX

    15,494.62
    -417.71 (-2.63%)
     
  • CAC 40

    7,027.11
    -167.05 (-2.32%)
     

Deep Lens Announces Launch of Real Time Feasibility Offering to Assist in Oncology Clinical Trial Design and Site Selection

·4-min read

Precision for Medicine utilizing new offering to accelerate oncology clinical trial enrollment

COLUMBUS, Ohio, December 07, 2021--(BUSINESS WIRE)--Deep Lens, a digital healthcare company focused on revolutionizing the oncology clinical trial recruitment process through artificial intelligence solutions, today announced the launch of its Real Time Feasibility offering, a new HIPAA-compliant tool designed to identify eligible patients and select the most effective sites in the Deep Lens Unity Network for oncology clinical trials in real-time. The Real Time Feasibility offering leverages Deep Lens’ proprietary cloud-based software solution, VIPER™, its network of research-capable community oncology sites and integrated workflows that combine EMR, lab and genomic data to gain real-time insight about specific patient populations. Precision for Medicine, a clinical research organization specializing in advanced therapies, is an early adopter of this new offering and will deploy the Deep Lens solution to assist its sponsors in rapidly identifying the sites and patients best suited for their oncology studies.

The identification and enrollment of precision oncology trials continues to be a challenge for many study sponsors. Many trials experience significant delays or fail to enroll enough patients to progress to the next stage of development, and those delays can lead to increased costs. The Journal of The American Medical Association (JAMA) estimates that it costs approximately $1 million per day to bring a cancer drug to market. Site selection is critical to ensuring on-time accrual; however, traditional feasibility studies rely on physicians estimating enrollment based on the number of patients seen in their clinical practice. These estimates often vary widely from the number of patients actually enrolled at that site.

"Although the number of oncology treatments has increased, there is more work to be done to ensure all patients are getting the best, most targeted therapies for their specific diseases. Clinical research must keep pace with the rate of scientific advancement, and that means clinical trials must be accessible to more patients," said Simon Arkell, President and Co-Founder of Deep Lens. "This new dashboard-based subscription offering provides any oncology-focused biopharma company or CRO the ability to quickly and easily view real-time patient counts across our fast-growing network to assess a study’s fit with any study. From there, it immediately deploys a trial enrollment project via the Unity Network, if appropriate. The use of AI enables scalable data analysis, and any new partner can be set up with real-time insights across our entire network in a matter of hours. It’s a game-changing evolution and we are delighted to partner with Precision for Medicine to bring these resources to sponsors and patients – compressing study timelines and getting the right patients into the right trials at the right time."

Deep Lens’ Real Time Feasibility offering provides trial sponsors and CROs the ability to view the number and de-identified location of current and future eligible patients for specific trials, in real-time. Through Deep Lens’ proprietary AI-based trial matching solution, VIPER, new patient data is being ingested and updated on a continuous basis from its robust Unity Network of community-based oncology practices. Instead of relying on historical data, Real Time Feasibility surfaces the patients that are eligible for trials now, and more importantly, those who may become eligible as their treatment progresses.

"Even with tremendous advances in our knowledge of diagnosing and treating cancer – precision oncology trials may struggle to find and enroll enough patients to progress to the next stage of development," said Megan Liles, Vice President, Clinical Solutions at Precision for Medicine. "Our vision is to streamline the clinical trial recruitment process for sponsors by giving them real-time, consistently updated patient insights so they can enroll trials faster and with more accuracy."

For more information about the Real Time Feasibility Offering or other Deep Lens services, please visit: www.deeplens.ai/real-time-feasibilty-dashboard.

About Deep Lens

Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows that combine lab, EMR, and genomic data to match cancer patients to clinical trials and precision therapies at the time of diagnosis, accelerating recruitment and compressing study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies. For more information, visit www.deeplens.ai.

About Precision for Medicine

Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 40 locations in the U.S., Canada, and Europe. For more information, visit https://www.precisionformedicine.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005428/en/

Contacts

Deep Lens Media Contact: Adrienne Kemp, media@deeplens.ai, + 949-922-0801

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting